©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Feb 27, 2024; 16(2): 112-114
Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.112
Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.112
New markers of fibrosis in hepatitis C: A step towards the Holy Grail?
Konstantinos John Dabos, Department of Hepatology, St Hohn's Hospital, Livingston EH54 6PP, West Lothian, United Kingdom
Author contributions: Dabos KJ wrote the manuscript.
Conflict-of-interest statement: Konstantinos Dabos declares no conflicts of interest.
Corresponding author: Konstantinos John Dabos, MD, PhD, Doctor, Department of Hepatology, St Hohn's Hospital, Howden Road West, Livingston EH54 6PP, West lothian, United Kingdom. konstantinos.dabos@nhslothian.scot.nhs.uk
Received: November 15, 2023
Peer-review started: November 15, 2023
First decision: December 5, 2023
Revised: December 12, 2023
Accepted: January 12, 2024
Article in press: January 12, 2024
Published online: February 27, 2024
Processing time: 104 Days and 1.6 Hours
Peer-review started: November 15, 2023
First decision: December 5, 2023
Revised: December 12, 2023
Accepted: January 12, 2024
Article in press: January 12, 2024
Published online: February 27, 2024
Processing time: 104 Days and 1.6 Hours
Core Tip
Core Tip: A novel approach for identifying non-invasive biomarkers as a step towards an accurate serological tool for fibrosis staging in hepatitis C.